SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ruiz-Irastorza, G
Right arrow Articles by Aguirre, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruiz-Irastorza, G
Right arrow Articles by Aguirre, C
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Lupus
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus

G Ruiz-Irastorza

Service and Department of Internal Medicine, Hospital de Cruces, Universidad del Pais Vasco/Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain, r.irastorza{at}euskalnet.net

M-V Egurbide

Service and Department of Internal Medicine, Hospital de Cruces, Universidad del Pais Vasco/Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain

A Martinez-Berriotxoa

Service and Department of Internal Medicine, Hospital de Cruces, Universidad del Pais Vasco/Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain

J Ugalde

Service and Department of Internal Medicine, Hospital de Cruces, Universidad del Pais Vasco/Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain

C Aguirre

Service and Department of Internal Medicine, Hospital de Cruces, Universidad del Pais Vasco/Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain

The aim of this study was to determine whether the different autoantibodies predict early damage in patients with systemic lupus erythematosus (SLE). The patients comprised a prospective inception cohort of 205 patients with SLE, 154 on follow-up for at least five years after diagnosis. Eight patients who died before the fifth year of disease course were included in analyses comprising survival. Organ damage was measured using the Systemic Lupus International Collaborating Clinics - American College of Rheumatology damage index (SDI). Endpoints were the development of some (SDI ≥1) or severe (SDI > 2) damage at five years after diagnosis or the combined outcome ‘SDI ≥1 or death at five years’. Autoantibodies [anti-DNA, anti-Ro, anti-La, anti-Sm, anti-U1 RNP, any anti-ENA and antiphospholipid (aPL)] were included in univariate and multivariate analysis. ‘Age at diagnosis’ was also included as an independent variable in multivariant analyses. Sapporo criteria were used to define aPL positivity. Eighty-four patients (54.5%) had accrued damage at five years, 17 patients (11.0%) having severe damage. Patients with aPL had damage in a higher proportion (63.2% any damage, 17.6% severe damage). Only aPL were related to damage in univariate analysis (P = 0.03). In logistic regression models, aPL were the only independent predictors of damage at five years (OR 1.94, 95% CI 1.01-3.73), severe damage at five years (OR 3.34, 95% CI 1.11-10.03) and increasing damage since diagnosis (OR 2.46, 95% CI 1.24-4.87). No autoantibody was a predictor of the outcome ‘SDI ≥1 or death at five years’. The conclusion was that aPL predict early damage in patients with SLE.

Key Words: anticardiolipin antibodies • autoantibodies • irreversible organ damage • lupus anticoagulant • morbidity • mortality

Lupus, Vol. 13, No. 12, 900-905 (2004)
DOI: 10.1191/0961203304lu2030oa


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
CJASNHome page
H. Wu, D. J. Birmingham, B. Rovin, K. V. Hackshaw, N. Haddad, D. Haden, C.-Y. Yu, and L. A. Hebert
D-Dimer Level and the Risk for Thrombosis in Systemic Lupus Erythematosus
Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1628 - 1636.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
D. Paran, D. Caspi, D. Levartovsky, O. Elkayam, I. Kaufman, I. Litinsky, G. Keren, and B. Koifman
Cardiac dysfunction in patients with systemic lupus erythematosus and antiphospholipid syndrome
Ann Rheum Dis, April 1, 2007; 66(4): 506 - 510.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
L M Vila, M J Molina, A M Mayor, R A Peredo, M L Santaella, and S Vila
Clinical and prognostic value of autoantibodies in Puerto Ricans with systemic lupus erythematosus
Lupus, December 1, 2006; 15(12): 892 - 898.
[Abstract] [PDF]



Advertisement